IL217746A - Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation - Google Patents
Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formationInfo
- Publication number
- IL217746A IL217746A IL217746A IL21774612A IL217746A IL 217746 A IL217746 A IL 217746A IL 217746 A IL217746 A IL 217746A IL 21774612 A IL21774612 A IL 21774612A IL 217746 A IL217746 A IL 217746A
- Authority
- IL
- Israel
- Prior art keywords
- aureus
- prevention
- treatment
- monoclonal antibody
- antibody against
- Prior art date
Links
- 101710092462 Alpha-hemolysin Proteins 0.000 title 1
- 101710197219 Alpha-toxin Proteins 0.000 title 1
- 101710124951 Phospholipase C Proteins 0.000 title 1
- 239000002776 alpha toxin Substances 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09010311A EP2284193A1 (en) | 2009-08-10 | 2009-08-10 | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| US26633009P | 2009-12-03 | 2009-12-03 | |
| PCT/EP2010/004884 WO2011018208A1 (en) | 2009-08-10 | 2010-08-10 | Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL217746A0 IL217746A0 (en) | 2012-03-29 |
| IL217746A true IL217746A (en) | 2016-05-31 |
Family
ID=41381987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217746A IL217746A (en) | 2009-08-10 | 2012-01-26 | Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9249215B2 (enExample) |
| EP (3) | EP2284193A1 (enExample) |
| JP (1) | JP6064241B2 (enExample) |
| KR (1) | KR101836130B1 (enExample) |
| CN (1) | CN102549013B (enExample) |
| CA (1) | CA2769394C (enExample) |
| ES (2) | ES2529175T3 (enExample) |
| IL (1) | IL217746A (enExample) |
| IN (1) | IN2012DN00797A (enExample) |
| RU (1) | RU2529946C9 (enExample) |
| WO (1) | WO2011018208A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013013323A1 (en) * | 2011-07-28 | 2013-01-31 | Cangene Corporation | Staphlococcus aureus alpha-hemolysin antibodies |
| WO2013093693A1 (en) * | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
| CA2870223A1 (en) * | 2012-04-17 | 2013-10-24 | Arsanis Biosciences Gmbh | Cross-reactive staphylococcus aureus antibody |
| SG11201503232TA (en) * | 2012-11-06 | 2015-05-28 | Medimmune Llc | Antibodies to s. aureus surface determinants |
| BR112015010126B1 (pt) | 2012-11-06 | 2022-11-01 | Medimmune, Llc | Uso de um anticorpo anti-alfa toxina (anti-at) de s. aureus isolado |
| CN104211804A (zh) * | 2014-08-20 | 2014-12-17 | 钱泓 | 一种抗金黄色葡萄球菌多克隆抗体的制备与应用 |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| US20220275088A1 (en) * | 2019-06-14 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| CN112538112B (zh) | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444171A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| US20230374114A1 (en) * | 2020-04-16 | 2023-11-23 | Dana-Farber Cancer Institute, Inc. | Coronavirus antibodies and methods of use thereof |
| CN113698478B (zh) * | 2020-05-21 | 2025-11-18 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| CN117106077B (zh) * | 2022-04-28 | 2024-07-16 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2255669A1 (en) * | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
| CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
| CN102743747A (zh) | 2006-06-12 | 2012-10-24 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
| JP5658564B2 (ja) * | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
-
2009
- 2009-08-10 EP EP09010311A patent/EP2284193A1/en not_active Withdrawn
-
2010
- 2010-08-10 IN IN797DEN2012 patent/IN2012DN00797A/en unknown
- 2010-08-10 WO PCT/EP2010/004884 patent/WO2011018208A1/en not_active Ceased
- 2010-08-10 EP EP14195810.8A patent/EP2860191B1/en active Active
- 2010-08-10 JP JP2012524142A patent/JP6064241B2/ja not_active Expired - Fee Related
- 2010-08-10 RU RU2012105045/10A patent/RU2529946C9/ru active
- 2010-08-10 US US13/388,254 patent/US9249215B2/en active Active
- 2010-08-10 CA CA2769394A patent/CA2769394C/en active Active
- 2010-08-10 EP EP10743037.3A patent/EP2464665B1/en active Active
- 2010-08-10 ES ES10743037.3T patent/ES2529175T3/es active Active
- 2010-08-10 KR KR1020127004737A patent/KR101836130B1/ko active Active
- 2010-08-10 ES ES14195810.8T patent/ES2651762T3/es active Active
- 2010-08-10 CN CN201080044958.0A patent/CN102549013B/zh active Active
-
2012
- 2012-01-26 IL IL217746A patent/IL217746A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769394C (en) | 2019-06-25 |
| JP6064241B2 (ja) | 2017-01-25 |
| ES2651762T3 (es) | 2018-01-29 |
| EP2464665B1 (en) | 2014-12-03 |
| EP2860191B1 (en) | 2017-10-11 |
| KR20120047270A (ko) | 2012-05-11 |
| CA2769394A1 (en) | 2011-02-17 |
| RU2529946C2 (ru) | 2014-10-10 |
| JP2013501506A (ja) | 2013-01-17 |
| EP2284193A1 (en) | 2011-02-16 |
| CN102549013A (zh) | 2012-07-04 |
| CN102549013B (zh) | 2015-05-06 |
| IN2012DN00797A (enExample) | 2015-06-26 |
| RU2012105045A (ru) | 2013-09-20 |
| KR101836130B1 (ko) | 2018-03-08 |
| US20120201829A1 (en) | 2012-08-09 |
| EP2464665A1 (en) | 2012-06-20 |
| ES2529175T3 (es) | 2015-02-17 |
| US9249215B2 (en) | 2016-02-02 |
| IL217746A0 (en) | 2012-03-29 |
| RU2529946C9 (ru) | 2015-03-27 |
| WO2011018208A1 (en) | 2011-02-17 |
| EP2860191A1 (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217746A (en) | Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation | |
| LTPA2021506I1 (lt) | Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui | |
| UA109658C2 (xx) | Антитіло проти cgrp | |
| UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
| BRPI1012853A2 (pt) | anticorpos humanizados específicos da forma protofibrilar do peptídeo beta-amiloide | |
| SMT201600182B (it) | Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio | |
| IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
| EP2638534A4 (en) | Cognitive increase in the presence of distraction and / or interruption | |
| BRPI0923747A2 (pt) | "tratamento de safras transgênicas com misturas de fiprolas e cloroniconilas". | |
| IL207217A (en) | Isolated and / or recombinant humanized antibody associated with human R5c and various aspects thereof | |
| MX2010004482A (es) | Anticuerpos anti-proteina g vsr. | |
| IL200610A0 (en) | Human monoclonal anti-ip-10 antibodies and uses thereof | |
| WO2009013543A3 (en) | Targeted binging agents directed to kdr and uses thereof - 035 | |
| BRPI0821211A2 (pt) | Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo. | |
| EP2288324A4 (en) | ABSORBENT HYGIENE WITH DISPENSER | |
| EP2322562A4 (en) | MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT | |
| CY2022028I1 (el) | Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας | |
| CR11126A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2 | |
| EP2739244A4 (en) | SYSTEMS, METHODS, AND IMPLANTS FOR TREATING PROLAPS OR INCONTINENCE | |
| BRPI0816234A2 (pt) | Derivado de ácido ascórbico ou sal do mesmo, método de produção do mesmo, e cosmético | |
| WO2009114560A3 (en) | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections | |
| PL2848258T3 (pl) | Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta | |
| ITMI20110598A1 (it) | Procedimento e apparecchio di comando per l'adattamento del rumore di marcia | |
| BRPI0818121A2 (pt) | diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização | |
| BR112013018454A2 (pt) | "anticorpo anti-p-selectina e seu uso no tratamento ou inibição de doenças trombóticas e inflamatórias, bem como composição que o compreende" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |